Last SFr.0.23 CHF
Change Today -0.01 / -4.17%
Volume 117.3K
CYTN On Other Exchanges
Symbol
Exchange
OTC US
SIX Swiss Ex
Frankfurt
As of 10:05 AM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

cytos biotechnology ag-reg (CYTN) Snapshot

Open
SFr.0.24
Previous Close
SFr.0.24
Day High
SFr.0.24
Day Low
SFr.0.23
52 Week High
10/10/13 - SFr.3.94
52 Week Low
04/14/14 - SFr.0.09
Market Cap
7.0M
Average Volume 10 Days
209.5K
EPS TTM
SFr.-1.26
Shares Outstanding
30.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYTOS BIOTECHNOLOGY AG-REG (CYTN)

Related News

No related news articles were found.

cytos biotechnology ag-reg (CYTN) Related Businessweek News

No Related Businessweek News Found

cytos biotechnology ag-reg (CYTN) Details

Cytos Biotechnology AG, a biopharmaceutical company, focuses on the discovery, development, and commercialization of biopharmaceutical products for use in the treatment and prevention of chronic diseases in Switzerland. The company’s lead product candidate is CYT003, which has completed Phase 2b clinical trials for the treatment of allergic asthma. It is developing CYT003 using Qb VLP platform, a vaccine platform based on bacteriophage Q beta-derived virus-like particles (Qb VLPs), which act as immune-stimulatory carriers for disease-associated antigens. The company has collaboration agreements with Novartis for the development of CAD106, an active immunotherapy for the treatment of patients with Alzheimer’s disease; Pfizer for developing a novel anti-IgE vaccine for Qb VLP platform; and Singapore’s Agency for Science, Technology and Research for the research, development, and commercialization of an influenza vaccine. Cytos Biotechnology AG is based in Schlieren, Switzerland.

28.7 Employees
Last Reported Date: 02/6/14

cytos biotechnology ag-reg (CYTN) Top Compensated Officers

Chairman, Chief Executive Officer and Member ...
Total Annual Compensation: SFr.701.7K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: SFr.561.9K
Executive Vice President for Corporate Develo...
Total Annual Compensation: SFr.376.7K
Compensation as of Fiscal Year 2013.

cytos biotechnology ag-reg (CYTN) Key Developments

Cytos Biotechnology AG Announces the Results of Global Phase 2b Clinical Trial with CYT003

Cytos Biotechnology AG announced that the Phase 2b study of CYT003 in patients with moderate to severe allergic asthma did not achieve a statistically significant reduction of the Asthma Control Questionnaire score at week 12 in the target patient population compared to placebo. Patients on placebo and at all dose levels of CYT003 achieved a clinically relevant improvement in their asthma control measured by ACQ. Additional endpoints, including lung function also failed to show a statistically significant difference to placebo. The clinical study was planned to continue with a blinded observation period of 9 months. Considering the clear outcome, Cytos has determined to unblind and terminate the clinical study.

Cytos Biotechnology AG, Annual General Meeting, Apr 03, 2014

Cytos Biotechnology AG, Annual General Meeting, Apr 03, 2014., at 10:00 Central European Standard Time.

Cytos Biotechnology AG to Report Q1, 2014 Results on May 02, 2014

Cytos Biotechnology AG announced that they will report Q1, 2014 results on May 02, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTN:SW SFr.0.23 CHF -0.01

CYTN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTN.
View Industry Companies
 

Industry Analysis

CYTN

Industry Average

Valuation CYTN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.0x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYTOS BIOTECHNOLOGY AG-REG, please visit www.cytos.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.